Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models

C.G . Langdon (1), N. Wiedemann (2), M.A. Held (1), J.T. Platt (1), F. Lévy (2), D. Robichon (2), C. Zanna (2), G. Vuagniaux (2), M. Sorensen (3), S. Wang (4), M.W. Bosenberg (1), D.F. Stern (1)

Presented at AACR 2014, San Diego, CA, USA

(1) Yale University, USA

(2) Debiopharm International SA, Switzerland

(3) Ascenta Therapeutics, USA

(4) University of Michigan Cancer Center, USA